Acadian Asset Management LLC purchased a new position in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 17,047 shares of the biopharmaceutical company’s stock, valued at approximately $793,000. Acadian Asset Management LLC owned 0.06% of Esperion Therapeutics as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of ESPR. Wasatch Advisors Inc. boosted its holdings in shares of Esperion Therapeutics by 13.4% in the first quarter. Wasatch Advisors Inc. now owns 637,789 shares of the biopharmaceutical company’s stock valued at $25,607,000 after acquiring an additional 75,165 shares in the last quarter. Pictet Asset Management Ltd. raised its holdings in Esperion Therapeutics by 13.6% in the 1st quarter. Pictet Asset Management Ltd. now owns 437,518 shares of the biopharmaceutical company’s stock valued at $17,566,000 after acquiring an additional 52,467 shares in the last quarter. Spark Investment Management LLC raised its holdings in Esperion Therapeutics by 72.1% in the 1st quarter. Spark Investment Management LLC now owns 390,900 shares of the biopharmaceutical company’s stock valued at $15,694,000 after acquiring an additional 163,800 shares in the last quarter. Pinnacle Associates Ltd. raised its holdings in Esperion Therapeutics by 4.0% in the 2nd quarter. Pinnacle Associates Ltd. now owns 187,549 shares of the biopharmaceutical company’s stock valued at $8,725,000 after acquiring an additional 7,225 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Esperion Therapeutics by 73.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 140,825 shares of the biopharmaceutical company’s stock valued at $6,875,000 after acquiring an additional 59,425 shares in the last quarter.
ESPR traded down $0.18 on Friday, hitting $36.56. The company’s stock had a trading volume of 279,136 shares, compared to its average volume of 435,372. Esperion Therapeutics Inc has a 12 month low of $33.13 and a 12 month high of $60.99. The company has a quick ratio of 5.65, a current ratio of 5.65 and a debt-to-equity ratio of 0.01. The firm has a market cap of $998.52 million, a P/E ratio of -4.85 and a beta of 1.71. The company’s 50 day simple moving average is $37.78 and its 200-day simple moving average is $44.26.
Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($2.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.86) by ($0.15). The business had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.05 million. During the same quarter in the previous year, the company earned ($1.71) EPS. Esperion Therapeutics’s quarterly revenue was up 9720.0% on a year-over-year basis. Equities analysts predict that Esperion Therapeutics Inc will post -3.02 earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on ESPR shares. ValuEngine lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, September 5th. Cowen reaffirmed a “buy” rating and set a $80.00 price target on shares of Esperion Therapeutics in a research report on Thursday, July 18th. Goldman Sachs Group cut shares of Esperion Therapeutics from a “neutral” rating to a “sell” rating and set a $50.00 price target on the stock. in a research report on Wednesday, May 29th. Northland Securities reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, August 29th. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, June 13th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $74.00.
In related news, major shareholder Target N. V. Biotech acquired 50,000 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The stock was purchased at an average price of $42.65 per share, with a total value of $2,132,500.00. Following the transaction, the insider now owns 3,572,964 shares of the company’s stock, valued at approximately $152,386,914.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Timothy M. Mayleben acquired 2,500 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were bought at an average cost of $35.25 per share, with a total value of $88,125.00. Following the transaction, the chief executive officer now directly owns 76,015 shares in the company, valued at approximately $2,679,528.75. The disclosure for this purchase can be found here. Insiders have bought 147,500 shares of company stock valued at $5,521,825 over the last three months. 7.70% of the stock is owned by corporate insiders.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Story: Momentum Investing
Receive News & Ratings for Esperion Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Esperion Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.